Menu Search
Equities

Ovoca Bio PLC

OVXA:BER

Ovoca Bio PLC

Actions
  • Price (EUR)0.0175
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+34.62%
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. It is also developing a new treatment for women affected by low libido or sex drive. It owns a patent portfolio that provides effective protection of its technology. The Company operates in Ireland, the United Kingdom and Russia.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-3.32m
  • Incorporated1985
  • Employees5.00
  • Location
    Ovoca Bio PLC17 Pembroke Street, UpperDUBLIN D02 AT22IrelandIRL
  • Phone+353 16619819
  • Fax+353 16619895
  • Websitehttps://ovocabio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.